IRWD - アイアンウッド・ファ―マシュ―ティカルズ (Ironwood Pharmaceuticals Inc.) アイアンウッド・ファ―マシュ―ティカルズ

 IRWDのチャート


 IRWDの企業情報

symbol IRWD
会社名 Ironwood Pharmaceuticals Inc (アイアンウッド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイアンウッド・ファーマシューティカルス(Ironwood Pharmaceuticals Inc.)はバイオテクノロジー企業である。同社は便秘過敏性腸症候群(IBS C)、慢性特発性便秘(CIC)、制御不能な痛風に関連する高尿酸血症、制御不能な胃食道逆流症(無制御性GERD)、血管および線維症等の分野の製品を開発する。同社は人体治療事業セグメントを運営する。同社の製品リナクロチドは「LINZESS」という商標名で米国のIBS CまたはCICに罹患している成人男性および女性に可能でき、商標名「CONSTELLA」で特定のヨーロッパ諸国のIBS Cに罹患している成人男性および女性に利用可能である。同社はまた、GERDを有する患者において対症的軽減をもたらす可能性のある胆汁酸封鎖剤の胃保持製剤IW-3718を開発する。血管・線維プログラムには可溶性グアニル酸シクラーゼ(sGC)を標的とするIW-1973およびIW-1701が含まれる。   アイアンウッド・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。消化器・循環器系疾患、疼痛、炎症などの治療薬の発見、開発、商業化に従事。主要製品には、成人の便秘を伴う慢性特発性便秘と過敏性腸症候群の治療薬「リンゼス」(リナクロチド)がある。欧州連合(EU)においての、この治療薬の商標名は「コンステラ」。本社はマサチュ―セッツ州。   Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
本社所在地 301 Binney Street Cambridge MA 02142 USA
代表者氏名 Peter M. Hecht Peter M. Hecht
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +1 617-621-7722
設立年月日 35796
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 730人
url www.ironwoodpharma.com
nasdaq_url https://www.nasdaq.com/symbol/irwd
adr_tso
EBITDA EBITDA(百万ドル) -46.26500
終値(lastsale) 17.89
時価総額(marketcap) 2739986136.46
時価総額 時価総額(百万ドル) 2559.26
売上高 売上高(百万ドル) 331.29400
企業価値(EV) 企業価値(EV)(百万ドル) 2785.16
当期純利益 当期純利益(百万ドル) -112.73600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ironwood Pharmaceuticals Inc. revenues increased 28% to $150.3M. Net loss decreased 4% to $92.5M. Revenues reflect Collaborative arrangements revenue increase of 15% to $134.3M Product revenue net increase from $754K to $1.7M. Lower net loss reflects loss decrease of 71% to $2.5M (expense) Loss on extinguishment of debt decrease from $2M (expense) to $0K.

 IRWDのテクニカル分析


 IRWDのニュース

   Ironwood Pharmaceuticals Provides Update on Impact of COVID-19  2020/03/26 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today provided an update on certain impacts of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus and help protect the safety and well-being of its employees, healthcare providers, patients and broader communities. “In the face of the COVID-19 pandemic, we are taking important steps in an effort to help slow the spread of this virus, prioritize the hea
   Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?  2020/03/14 15:30:47 Zacks Investment Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates  2020/02/14 14:50:00 Zacks Investment Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
   Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance  2020/02/13 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2019 results and recent business performance. “2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients,” said Mark Mallon, chief executive officer of Ironwood. “To do this, we are executing on
   What's in Store for Ironwood (IRWD) This Earnings Season?  2020/02/10 15:13:00 Zacks Investment Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
   Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?  2020/03/14 15:30:47 Zacks Investment Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates  2020/02/14 14:50:00 Zacks Investment Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
   Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance  2020/02/13 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2019 results and recent business performance. “2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients,” said Mark Mallon, chief executive officer of Ironwood. “To do this, we are executing on
   What's in Store for Ironwood (IRWD) This Earnings Season?  2020/02/10 15:13:00 Zacks Investment Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
   Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?  2020/02/06 17:31:01 Zacks Investment Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates  2020/02/14 14:50:00 Zacks Investment Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
   Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance  2020/02/13 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2019 results and recent business performance. “2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients,” said Mark Mallon, chief executive officer of Ironwood. “To do this, we are executing on
   What's in Store for Ironwood (IRWD) This Earnings Season?  2020/02/10 15:13:00 Zacks Investment Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
   Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?  2020/02/06 17:31:01 Zacks Investment Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call  2020/01/30 21:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full- year 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 13, 2020. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 1975039. To access the webcast, please visit the Investors section of Ironwood’s website at www.iron

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイアンウッド・ファ―マシュ―ティカルズ IRWD Ironwood Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)